Background Lopinavir-ritonavir is a repurposed drug for coronavirus disease-2019 (COVID-
19). In this study, a pooled effect of lopinavir-ritonavir on mortality, virological cure …

Since December 2019, the world was encountered a new disease called coronavirus
disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 …

Abstract Coronavirus Disease 2019 (COVID-19) has been a global health crisis since it was
first identified in December 2019. In addition to fever, cough, headache, and shortness of …

Since the outbreak of the COVID-19 pandemic, the use of antiviral and other available drugs
has been considered to combat or reduce the clinical symptoms of patients. In this regard, it …

Patients with coronavirus disease 2019 (COVID‐19) may experience a cytokine storm with
elevated interleukin‐6 (IL‐6) levels in response to severe acute respiratory syndrome …

Most models of COVID-19 are implemented at a single micro or macro scale, ignoring the
interplay between immune response, viral dynamics, individual infectiousness and …

Despite effective antiretroviral therapy (ART), HIV infected individuals throughout the world
remain at significant risk of respiratory infections and non-communicable disease. Severe …

Background Population pharmacokinetic analysis in critically ill infants remains a challenge
for lack of information. Objectives To determine the population pharmacokinetic parameters …

The global epidemic outbreak of the coronavirus disease 2019 (COVID-19), which exhibits
high infectivity, resulted in thousands of deaths due to the lack of specific drugs. Certain …

Objectives Antiviral interventions are required to complement vaccination programmes and
reduce the global burden of COVID-19. Prior to initiation of large-scale clinical trials, robust …